ABBV icon

AbbVie

211.96 USD
--6.08
2.79%
At close Updated Nov 3, 4:00 PM EST
Pre-market
After hours
211.95
--0.01
0%
1 day
-2.79%
5 days
-6.63%
1 month
-9.38%
3 months
7.49%
6 months
8.1%
Year to date
18.12%
1 year
5.73%
5 years
140.97%
10 years
239.52%
 

About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Employees: 55,000

0
Funds holding %
of 7,506 funds
0
Analysts bullish %
of 11 analysts
0
Positive news %
of 64 articles
Price charts implemented using Lightweight Charts™